Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Mouse (Murine) TRAF6 Anticorps:
anti-Human TRAF6 Anticorps:
anti-Rat (Rattus) TRAF6 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal TRAF6 Primary Antibody pour WB - ABIN1881900
Hinz, Stilmann, Arslan, Khanna, Dittmar, Scheidereit: A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation. dans Molecular cell 2010
Show all 4 Pubmed References
Cow (Bovine) Polyclonal TRAF6 Primary Antibody pour IHC (fro), IHC (p) - ABIN537432
Ichii, Otsuka, Sasaki, Namiki, Hashimoto, Kon: Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. dans Kidney international 2012
Show all 3 Pubmed References
Human Polyclonal TRAF6 Primary Antibody pour ICC, ELISA - ABIN1003297
Takeda, Kaisho, Akira: Toll-like receptors. dans Annual review of immunology 2003
Show all 4 Pubmed References
Human Polyclonal TRAF6 Primary Antibody pour FACS, WB - ABIN4361690
Yoshida, Jono, Kai, Li: The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. dans The Journal of biological chemistry 2005
Show all 2 Pubmed References
Human Polyclonal TRAF6 Primary Antibody pour ICC, IHC (fro) - ABIN3044469
Yuan, Zhang, Yang: Ligusticum wallichii Extract Inhibited the Expression of IL-1? after AMI in Rats. dans Evidence-based complementary and alternative medicine : eCAM 2014
Show all 2 Pubmed References
Human Polyclonal TRAF6 Primary Antibody pour ELISA, ICC - ABIN4361694
Doyon, Servant et al.: Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkappaB kinase ... dans The Journal of biological chemistry 2010
Cow (Bovine) Polyclonal TRAF6 Primary Antibody pour IHC, IHC (p) - ABIN4361692
Zapata, Krajewska, Krajewski, Kitada, Welsh, Monks, McCloskey, Gordon, Kipps, Gascoyne, Shabaik, Reed: TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. dans Journal of immunology (Baltimore, Md. : 1950) 2000
Human Polyclonal TRAF6 Primary Antibody pour IF (p) - ABIN918441
Qi, Pradipta, Li, Zhao, Lu, Fu, Wei, Hsung, Tanaka, Zhou: Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6. dans Journal of experimental & clinical cancer research : CR 2017
we found that reactive oxygen species-induced autophagy acts as a negative feedback regulator of JNK (Montrer MAPK8 Anticorps) activity by dissociating Atg9 (Montrer ATG9A Anticorps)/mAtg9 (Montrer ATG9A Anticorps) from dTRAF2/TRAF6 in Drosophila.
null mutant of DTRAF2 showed immune deficiencies in which NF-kappaB nuclear translocation and antimicrobial gene transcription against microbial infection were severely impaired
TRAF6 coiled-coil oligomerization domain primes its interaction with Ubc13 (Montrer UBE2N Anticorps)/Ub~Ubc13 (Montrer UBE2N Anticorps) to confer processivity. Long polyUb chain assembly requires coiled-coil domain of TRAF6
TRAF6 is a key promoter of ischemic signaling cascades and neuronal death after cerebral ischemia/reperfusion injury. TRAF6 upregulation binds and ubiquitinates Rac1 directly, which promotes neuron death through neuroinflammation and neuro-oxidative signals.
Data provide a novel association between WDFY3 (Montrer WDFY3 Anticorps) and the RANKL (Montrer TNFSF11 Anticorps)-induced osteoclastogenesis pathway via the modulation of TRAF6.
this study shows that TRAF6 is necessary for the nontranscriptional priming of NLRP3 (Montrer NLRP3 Anticorps) inflammasome by TLR/IL-1R derived signals
work reveals that simulated microgravity promotes the apoptotic response through a combined modulation of the Uev1A/TICAM/TRAF (Montrer TRAF1 Anticorps)/NF-kappaB (Montrer NFKB1 Anticorps)-regulated apoptosis and the p53 (Montrer TP53 Anticorps)/PCNA (Montrer PCNA Anticorps)- and ATM (Montrer ATM Anticorps)/ATR (Montrer ATR Anticorps)-Chk1 (Montrer CHEK1 Anticorps)/2-controlled DNA-damage response pathways.
TRAF6 prevents the mitochondrial translocation of p53 (Montrer TP53 Anticorps) and spontaneous apoptosis by promoting lysine63-linked ubiquitination of p53 (Montrer TP53 Anticorps) in cytosol.
TRAF6 mediates lysine-63 ubiquitination within the SH2 (Montrer MYO15 Anticorps) domain of STAT3 (Montrer STAT3 Anticorps), which is an essential step for STAT3 (Montrer STAT3 Anticorps) membrane recruitment and phosphorylation in response to S Typhimurium infection; results reveal a strategy in which S Typhimurium T3SS effectors broaden their functions through the activation of host proteins in a ubiquitination-dependent manner to manipulate host cells into becoming a Salmonella-friendly zone
this study shows that an interaction of TRAF6 with cullin-5 (Montrer CUL5 Anticorps) promotes TRAF6 polyubiquitination and lipopolysaccharide signaling
Consistent with cellular studies, icaritin downregulated TRAF6 and NFATc1 protein expression in CD11b(+) /Gr-1(-/low) osteoclast precursors
Data (including data from studies using knockout mice) suggest that RANKL (Montrer TNFSF11 Anticorps) enhances TNF (Montrer TNF Anticorps)-induced osteoclast formation from precursor spleen cells and enhances bone resorption independently of Traf6 by degrading Traf3 (Montrer TRAF3 Anticorps), a known inhibitor of osteoclastogenesis. (RANKL (Montrer TNFSF11 Anticorps) = osteoclast differentiation factor (Montrer TNFSF11 Anticorps); TNF (Montrer TNF Anticorps) = tumor necrosis factor (Montrer TNF Anticorps); Traf (Montrer TRAF1 Anticorps) = TNF (Montrer TNF Anticorps) receptor-associated factor)
we have now analyzed the in vivo function of Traf6 in the innate immune response without interference of adaptive immunity
Full-length traf6 was functionally characterized.
Results identified TRAF6 as a direct target of miR (Montrer MLXIP Anticorps)-429, and its downregulation partially attenuates the effect of miR (Montrer MLXIP Anticorps)-429 in promoting hepatocellular carcinoma cell proliferation and motility.
Compared with normal chondrocytes, the expression of miR (Montrer MLXIP Anticorps)-146a decreased, while the mRNA and protein expressions of TRAF6 and NF-kappaB (Montrer NFKB1 Anticorps) increased in osteoarthritis chondrocytes.
We report two siblings with SCID (Montrer PRKDC Anticorps) and an atypical phenotype of osteopetrosis (OP (Montrer CSF1 Anticorps)). A biallelic microdeletion encompassing the 5' region of TRAF6, RAG1 (Montrer RAG1 Anticorps) and RAG2 (Montrer RAG2 Anticorps) genes was identified. TRAF6, a tumor necrosis factor (Montrer TNF Anticorps) receptor-associated family member, plays an important role in T cell signaling and in RANKL (Montrer TNFSF11 Anticorps)-dependent osteoclast differentiation and activation but its role in human OP has not been previously reported
miR (Montrer MLXIP Anticorps)-146a improves intestine epithelial cells survival under ischemia and I/R injury through inhibition TLR4 (Montrer TLR4 Anticorps), TRAF6, and p-IkappaBalpha (Montrer NFKBIA Anticorps), subsequently leading to decreased NF-kappaB (Montrer NFKB1 Anticorps) p65 (Montrer GORASP1 Anticorps) nuclear translocation.
Taken together, these results define a novel role for miR (Montrer MLXIP Anticorps)-146a as a negative regulator of dengue virus-induced autophagy and identify TRAF6 as a key target of this microRNA in modulating the dengue virus-autophagy interaction.
These data define that YOD1 (Montrer YOD1 Anticorps) antagonizes TRAF6/p62 (Montrer GTF2H1 Anticorps)-dependent IL-1 (Montrer IL1A Anticorps) signaling to NF-kappaB (Montrer NFKB1 Anticorps).
high expression of TRAF6 is significant for esophageal cancer progression, and TRAF6 indicates poor prognosis in esophageal cancer patients.
CRBN (Montrer CRBN Anticorps) negatively regulates TLR4 (Montrer TLR4 Anticorps) signaling via attenuation of TRAF6 and TAB2 (Montrer TAB2 Anticorps) ubiquitination.
the polymorphisms in TLR-MyD88 (Montrer MYD88 Anticorps)-NF-kappaB (Montrer NFKB1 Anticorps) signaling pathway confer genetic susceptibility to Type 2 diabetes mellitus and diabetic nephropathy.
The protein encoded by this gene is a member of the TNF receptor associated factor (TRAF) protein family. TRAF proteins are associated with, and mediate signal transduction from, members of the TNF receptor superfamily. This protein mediates signaling from members of the TNF receptor superfamily as well as the Toll/IL-1 family. Signals from receptors such as CD40, TNFSF11/RANCE and IL-1 have been shown to be mediated by this protein. This protein also interacts with various protein kinases including IRAK1/IRAK, SRC and PKCzeta, which provides a link between distinct signaling pathways. This protein functions as a signal transducer in the NF-kappaB pathway that activates IkappaB kinase (IKK) in response to proinflammatory cytokines. The interaction of this protein with UBE2N/UBC13, and UBE2V1/UEV1A, which are ubiquitin conjugating enzymes catalyzing the formation of polyubiquitin chains, has been found to be required for IKK activation by this protein. This protein also interacts with the transforming growth factor (TGF) beta receptor complex and is required for Smad-independent activation of the JNK and p38 kinases. This protein has an amino terminal RING domain which is followed by four zinc-finger motifs, a central coiled-coil region and a highly conserved carboxyl terminal domain, known as the TRAF-C domain. Two alternatively spliced transcript variants, encoding an identical protein, have been reported.
TNF receptor-associated factor 6-B
, E3 ubiquitin-protein ligase TRAF6
, TNF-receptor-associated factor 2
, TNF receptor-associated factor 6
, TNF receptor-associated factor 6-like
, RING finger protein 85
, interleukin-1 signal transducer
, TNF-receptor associated factor 6